1
|
Eslamkhah S, Aslan ES, Yavas C, Akcalı N, Batur LK, Abuaisha A, Yildirim EE, Solak M, White KN. Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2025:10.1007/s00210-024-03649-9. [PMID: 39777535 DOI: 10.1007/s00210-024-03649-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2024] [Accepted: 11/18/2024] [Indexed: 01/11/2025]
Abstract
Mpox, formerly known as monkeypox, is a zoonotic disease caused by the Mpox virus (MPXV), which has recently attracted global attention due to its potential for widespread outbreaks. Initially identified in 1958, MPXV primarily spreads to humans through contact with infected wild animals, particularly rodents. Historically confined to Africa, the virus has expanded beyond endemic regions, with notable outbreaks in Europe and North America in 2022, especially among men who have sex with men (MSM). The World Health Organization (WHO) has declared the current Mpox outbreak a Public Health Emergency of International Concern. This review explores the epidemiology, pathophysiology, and clinical manifestations of MPXV, along with current treatment strategies and the role of mRNA vaccines. It emphasizes the importance of understanding the changing dynamics of Mpox transmission, which are influenced by factors such as waning immunity from smallpox vaccinations and increased global interconnectedness. The potential for developing multi-epitope vaccines that can stimulate robust immune responses is highlighted, showcasing how bioinformatics can facilitate the identification of immunogenic antigens. Continued research and investment in vaccine development are crucial to address the urgent need for effective candidates that can protect at-risk populations. In summary, this review underscores the necessity for proactive public health measures and collaborative efforts among healthcare authorities, researchers, and communities to mitigate the impact of Mpox and enhance global preparedness for future outbreaks.
Collapse
Affiliation(s)
- Sajjad Eslamkhah
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Elif Sibel Aslan
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Cuneyd Yavas
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Nermin Akcalı
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Lutfiye Karcıoglu Batur
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Asmaa Abuaisha
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Erva Esma Yildirim
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, 34015, Turkey
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey
| | - Mustafa Solak
- Biruni University Research Center (B@MER), Biruni University, Istanbul, 34015, Turkey.
- Department of Medical Genetics, Faculty of Medicine, Biruni University, Merkezefendi Mahallesi G/75 Sk. No: 1-13, Zeytinburnu, Istanbul, 34010, Turkey.
| | - Kenneth N White
- School of Human Sciences, London Metropolitan University, London, UK
| |
Collapse
|
2
|
Obermeier PE, Buder SC, Hillen U. Pockenvirusinfektionen in der Dermatologie: Poxvirus infections in dermatology - the neglected, the notable, and the notorious. J Dtsch Dermatol Ges 2024; 22:56-96. [PMID: 38212918 DOI: 10.1111/ddg.15257_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 08/20/2023] [Indexed: 01/13/2024]
Abstract
ZusammenfassungDie Familie Poxviridae umfasst derzeit 22 Gattungen, die Wirbeltiere infizieren können. Humanpathogene Pockenviren gehören den Gattungen Ortho‐, Para‐, Mollusci‐ und Yatapoxvirus an. Bis zur Eradikation der Variola vera im Jahr 1979 waren die Pocken, im Volksmund auch Blattern genannt, eine schwerwiegende Gesundheitsbedrohung für die Bevölkerung. Noch heute sind Dermatologen mit zahlreichen Pockenvirusinfektionen konfrontiert, wie den Bauernhofpocken, die als Zoonosen nach Tierkontakten in ländlichen Gebieten oder nach Massenversammlungen auftreten können. In den Tropen können Erkrankungen durch Tanapox‐ oder Vaccinia‐Viren zu den Differenzialdiagnosen gehören. Dellwarzen sind weltweit verbreitet und werden in bestimmten Fällen als sexuell übertragbare Pockenvirusinfektion angesehen. In jüngster Zeit hatten sich Mpox (Affenpocken) zu einer gesundheitlichen Notlage von internationaler Tragweite entwickelt, die eine rasche Identifizierung und angemessene Behandlung durch Dermatologen und Infektiologen erfordert. Fortschritte und neue Erkenntnisse über Epidemiologie, Diagnose, klinische Manifestationen und Komplikationen sowie Behandlung und Prävention von Pockenvirusinfektionen erfordern ein hohes Maß an Fachwissen und interdisziplinärer Zusammenarbeit in den Bereichen Virologie, Infektiologie und Dermatologie. Dieser CME‐Artikel bietet einen aktualisierten systematischen Überblick, um praktizierende Dermatologen bei der Identifizierung, Differenzialdiagnose und Behandlung klinisch relevanter Pockenvirusinfektionen zu unterstützen.
Collapse
Affiliation(s)
- Patrick E Obermeier
- Klinik für Dermatologie und Venerologie, Vivantes Klinikum Neukölln, Berlin, Deutschland
- Abteilung für Infektionskrankheiten, Vaccine Safety Initiative, Berlin, Deutschland
| | - Susanne C Buder
- Klinik für Dermatologie und Venerologie, Vivantes Klinikum Neukölln, Berlin, Deutschland
- Konsiliarlabor für Gonokokken, Fachgebiet Sexuell übertragbare bakterielle Krankheitserreger, Robert Koch-Institut, Berlin, Deutschland
| | - Uwe Hillen
- Klinik für Dermatologie und Venerologie, Vivantes Klinikum Neukölln, Berlin, Deutschland
| |
Collapse
|
3
|
Obermeier PE, Buder SC, Hillen U. Poxvirus infections in dermatology - the neglected, the notable, and the notorious. J Dtsch Dermatol Ges 2024; 22:56-93. [PMID: 38085140 DOI: 10.1111/ddg.15257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 08/20/2023] [Indexed: 12/22/2023]
Abstract
The family Poxviridae currently comprises 22 genera that infect vertebrates. Of these, members of the Ortho-, Para-, Mollusci- and Yatapoxvirus genera have been associated with human diseases of high clinical relevance in dermatology. Historically, smallpox had been a notorious health threat until it was declared eradicated by the World Health Organization in 1979. Today, dermatologists are confronted with a variety of poxviral infections, such as farmyard pox, which occurs as a zoonotic infection after contact with animals. In the tropics, tanapox or vaccinia may be in the differential diagnosis as neglected tropical dermatoses. Molluscum contagiosum virus infection accounts for significant disease burden worldwide and is classified as a sexually transmitted infection in certain scenarios. Recently, mpox (monkeypox) has emerged as a public health emergency of international concern, requiring rapid recognition and appropriate management by dermatologists and infectious disease specialists. Advances and new insights into the epidemiology, diagnosis, clinical manifestations and complications, treatment, and prevention of poxviral infections require a high level of expertise and interdisciplinary skills from healthcare professionals linking virology, infectious diseases, and dermatology. This CME article provides a systematic overview and update to assist the practicing dermatologist in the identification, differential diagnosis, and management of poxviral infections.
Collapse
Affiliation(s)
- Patrick E Obermeier
- Department of Dermatology and Venereology, Vivantes Hospital Neukölln, Berlin, Germany
- Department of Infectious Diseases, Vaccine Safety Initiative, Berlin, Germany
| | - Susanne C Buder
- Department of Dermatology and Venereology, Vivantes Hospital Neukölln, Berlin, Germany
- German Reference Laboratory for Gonococci, Unit Sexually Transmitted Bacterial Pathogens, Department for Infectious Diseases, Robert Koch-Institute, Berlin, Germany
| | - Uwe Hillen
- Department of Dermatology and Venereology, Vivantes Hospital Neukölln, Berlin, Germany
| |
Collapse
|
4
|
Estévez S, Vara M, Gamo M, Manzano S, Troya J, Botezat E, Jiménez E, Pedrero-Tomé R, Martin MÁ, de la Cueva P, Fernández E, Fernández B, Brown DE, Palma E, Simón A. Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role? J Clin Med 2023; 12:4124. [PMID: 37373818 DOI: 10.3390/jcm12124124] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 06/09/2023] [Accepted: 06/15/2023] [Indexed: 06/29/2023] Open
Abstract
MPOX (monkeypox) is a zoonotic viral disease, endemic in some Central and West African countries. However, in May 2022, cases began to be reported in non-endemic countries, demonstrating community transmission. Since the beginning of the outbreak, different epidemiological and clinical behaviors have been observed. We conducted an observational study at a secondary hospital in Madrid to characterize suspected and confirmed cases of MPOX epidemiologically and clinically. Besides the general descriptive analysis, we compared data between HIV-positive and HIV-negative subjects; 133 patients were evaluated with suspected MPOX, of which 100 were confirmed. Regarding positive cases, 71.0% were HIV positive, and 99.0% were men with a mean age of 33. In the previous year, 97.6% reported having sex with men, 53.6% used apps for sexual encounters, 22.9% practiced chemsex, and 16.7% went to saunas. Inguinal adenopathies were significantly higher in MPOX cases (54.0% vs. 12.1%, p < 0.001), as the involvement of genital and perianal area (57.0% vs. 27.3% and 17.0% vs. 1.0%, p = 0.006 and p = 0.082 respectively). Pustules were the most common skin lesion (45.0%). In HIV-positive cases, only 6.9% had a detectable viral load, and the mean CD4 count was 607.0/mm3. No significant differences were observed in the disease course, except for a greater tendency towards the appearance of perianal lesions. In conclusion, the MPOX 2022 outbreak in our area has been related to sexual intercourse among MSM, with no severe clinical cases nor apparent differences in HIV and non-HIV patients.
Collapse
Affiliation(s)
- Samuel Estévez
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Marta Vara
- Department of Preventive Medicine and Public Health, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - María Gamo
- Department of Dermatology, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Samuel Manzano
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Jesús Troya
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Ekaterina Botezat
- Department of Preventive Medicine and Public Health, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Eva Jiménez
- Department of Preventive Medicine and Public Health, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Roberto Pedrero-Tomé
- Foundation for Biomedical Research and Innovation (FIIB), Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - María Ángeles Martin
- Department of Dermatology, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Pablo de la Cueva
- Department of Dermatology, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Elisa Fernández
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Beatriz Fernández
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - David Esteban Brown
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Elena Palma
- Department of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain
| | - Ana Simón
- Department of Dermatology, Infanta Leonor University Hospital, 28031 Madrid, Spain
| |
Collapse
|
5
|
Rozas-Muñoz E, Blamey-Diaz R, Piquero-Casals J, Mir-Bonafé JF, Ocampo-López C, Madariaga JA. Perianal Vesiculopustular Eruption in a Young Man: Answer. Am J Dermatopathol 2023; 45:201-202. [PMID: 36791371 DOI: 10.1097/dad.0000000000002363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
| | | | - Jaime Piquero-Casals
- Department of Dermatology, Clínica dermatológica multidisciplinar Dermik, Barcelona, Spain
| | | | | | - Juan-Andres Madariaga
- Department of Anatomic Pathology, Hospital San Pablo, Universidad Catolica del Norte, Coquimbo, Chile
| |
Collapse
|
6
|
Dinulos JE, Dinulos JG. Present and future: infectious tropical travel rashes and the impact of climate change. Ann Allergy Asthma Immunol 2022; 130:452-462. [PMID: 36574899 PMCID: PMC9789609 DOI: 10.1016/j.anai.2022.12.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 12/16/2022] [Accepted: 12/19/2022] [Indexed: 12/25/2022]
Abstract
In this article, we discuss pertinent cutaneous findings with which patients may present after travel to tropical destinations. We address arthropod-borne infectious diseases such as cutaneous leishmaniasis, Chagas disease, cutaneous larva migrans, and myiasis. We discuss other relevant diseases with cutaneous signs such as monkey pox and severe acute respiratory syndrome coronavirus 2. We provide clinicians with information regarding the background, diagnosis, treatment, and prevention of these tropical rashes. In addition, we address the impact that climate change will have on the temporal and geographic incidence of these rashes. Viral, fungal, and vector-borne diseases have seen a geographic expansion into more northern latitudes. Among these are tick-borne Lyme disease, aquatic snail-related seabather's eruption, and atopic dermatitis. As these diseases spread, we believe that the updated information within this article is significant to the practicing physician in today's warming world.
Collapse
Affiliation(s)
| | - James G Dinulos
- Seacoast Dermatology, PLLC, Portsmouth, New Hampshire; Department of Dermatology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; Department of Dermatology, University of Connecticut School of Medicine, Framingham, Connecticut.
| |
Collapse
|
7
|
Gul I, Liu C, Yuan X, Du Z, Zhai S, Lei Z, Chen Q, Raheem MA, He Q, Hu Q, Xiao C, Haihui Z, Wang R, Han S, Du K, Yu D, Zhang CY, Qin P. Current and Perspective Sensing Methods for Monkeypox Virus. Bioengineering (Basel) 2022; 9:571. [PMID: 36290539 PMCID: PMC9598380 DOI: 10.3390/bioengineering9100571] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 10/13/2022] [Accepted: 10/14/2022] [Indexed: 11/17/2022] Open
Abstract
The outbreak of the monkeypox virus (MPXV) in non-endemic countries is an emerging global health threat and may have an economic impact if proactive actions are not taken. As shown by the COVID-19 pandemic, rapid, accurate, and cost-effective virus detection techniques play a pivotal role in disease diagnosis and control. Considering the sudden multicountry MPXV outbreak, a critical evaluation of the MPXV detection approaches would be a timely addition to the endeavors in progress for MPXV control and prevention. Herein, we evaluate the current MPXV detection methods, discuss their pros and cons, and provide recommended solutions to the problems. We review the traditional and emerging nucleic acid detection approaches, immunodiagnostics, whole-particle detection, and imaging-based MPXV detection techniques. The insights provided in this article will help researchers to develop novel techniques for the diagnosis of MPXV.
Collapse
Affiliation(s)
- Ijaz Gul
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Changyue Liu
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Xi Yuan
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Zhicheng Du
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Shiyao Zhai
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Zhengyang Lei
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Qun Chen
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Muhammad Akmal Raheem
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Qian He
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Qiuyue Hu
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Chufan Xiao
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Zhang Haihui
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Runming Wang
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Sanyang Han
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| | - Ke Du
- Chemical and Environmental Engineering, University of California, Riverside, CA 92521, USA;
| | - Dongmei Yu
- School of Mechanical, Electrical & Information Engineering, Shandong University, Weihai 264209, China
| | - Can Yang Zhang
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
| | - Peiwu Qin
- Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China; (I.G.); (C.L.); (X.Y.); (Z.D.); (S.Z.); (Z.L.); (Q.C.); (M.A.R.); (Q.H.); (Q.H.); (C.X.); (Z.H.); (R.W.); (S.H.)
- Tsinghua-Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| |
Collapse
|